MAPS and MAPS Public Benefit Corporation Announce Positive Result from Phase 3 Trial of MDMA-Assisted Therapy for PTSD
MAPS-Sponsored Pilot Study Shows MDMA-Assisted Therapy for PTSD in Couples Can Reduce PTSD Symptoms and Improve Couples’ Happiness
December 23, 2020
Dear friends and supporters,
In November 2020, MAPS Public Benefit Corporation (MAPS PBC) completed data analysis of the first of two Phase 3 trials of MDMA-assisted therapy for treatment of posttraumatic stress disorder (PTSD). The results confirmed Phase 2 results and prior expectations from an independent interim analysis which determined there was a 90% or greater probability that the trial, when completed, would be of sufficient size to detect statistically significant results. Further, no unexpected or serious safety signals emerged during the course of the trial.
The results indicate MDMA-assisted therapy for PTSD may be an effective treatment for PTSD resulting from various types of trauma, including trauma occurring in childhood and in patients with dissociative subtype of PTSD, pending assessment by the U.S. Food and Drug Administration (FDA). Based on these results, MAPS will begin discussions with the FDA on ways to accelerate the timeframe for approval of this modality. The Phase 3 trial, the first of its kind in scope and size, treated 90 participants who received 3 day-long MDMA or placebo sessions one month apart and 12 90-minute non-drug therapy sessions over approximately 3.5 months. Read the full update here.
“MAPS is on track towards our goal of obtaining FDA approval if we can successfully complete our second Phase 3 study and other associated safety studies that the FDA has required. We now can say with certainty that the $30 million recently raised by MAPS, the Psychedelic Science Funders Collaborative (PSFC), author Tim Ferriss, and all other donors in our Capstone Campaign will be sufficient to generate all of the research data we need prior to submitting an NDA to the FDA, and then to Health Canada and the Israeli Ministry of Health,” explains MAPS Founder Rick Doblin, Ph.D. “In order to bring the therapeutic potential of MDMA-assisted psychotherapy for PTSD to the estimated 350 million people around the world who suffer from PTSD, MAPS is now launching a new $30 million campaign to raise the funds necessary to conduct Phase 3 research in Europe for approval by the European Medicines Agency (EMA) and to globalize regulatory approval in many countries of the world.” Read more in From the Desk of Rick Doblin, Ph.D., here.
We’re pleased to announce the recent publication of the results of a MAPS-sponsored pilot study published on December 7, 2020, in the European Journal of Psychotraumatology. The study found that MDMA-assisted therapy for PTSD in couples may reduce PTSD symptoms and improve couples’ happiness. Cognitive-Behavioral Conjoint Therapy (CBCT) for PTSD and MDMA-assisted therapy for PTSD resulted in significant reductions in PTSD symptoms and relational outcomes for couples. This initial trial included six couples with a range of baseline relationship satisfaction in which one member was diagnosed with PTSD resulting from a range of traumas including childhood physical abuse, childhood sexual abuse, and active military service. Read the press release here.
In 2019, the Journal of Psychoactive Drugs published a case study of one couple involved in our Cognitive-Behavioral Conjoint Therapy (CBCT) for PTSD trial. The couple was chosen to provide a demographically representative example of the study participants as well as a detailed account of the methodology and choices made to integrate CBCT and MDMA. An account of their experience through the treatment can be read here.
Dr. Lyle Craker of the University of Massachusetts – Amherst, supported by MAPS, has filed a lawsuit in the U.S. District Court in Massachusetts to compel the Drug Enforcement Administration (DEA) to end their delay and process marijuana producer and manufacturer license applications to allow sanctioned scientific research toward a viable medical cannabis pharmaceutical product. Efforts to conduct meaningful research into cannabis medicines have been blocked for decades; the continued obstruction is causing suffering for people with serious conditions. Read the press release here.
Concluding a process that started in March with its announcement of a new rule governing the application of bulk manufacture licenses for marijuana, on December 17, 2020, DEA issued a final rule that essentially establishes DEA as a clearinghouse for all production and sale of federally legal cannabis. Instead of simplifying the process and acting on the dozens of pending applications, DEA’s new rules have failed to meaningfully address the field’s urgent needs for medicine and instead, add additional administrative hurdles that will ultimately hurt people seeking relief from medical cannabis.
For the last two decades, the U.S. Department of Justice has inconsistently applied international treaty obligations to justify a monopoly on production of cannabis by a single grower, while utterly failing to act on applications from other qualified producers, like Dr. Lyle Craker. Given the progress occurring at the United Nations, in other countries around the world, and with state-legal systems here in the United States, we are particularly disappointed to see the federal government continue to dig its heels in and restrict science. For more information and context, read this article from Marijuana Moment.
On Sunday, December 20, the CNN original series This is Life with Lisa Ling broadcasted a new investigative report on the potential healing effects of psychedelics. In this new episode, journalist Lisa Ling interviews MAPS Founder Rick Doblin, Ph.D., and other notable figures in the field of psychedelic therapy. This special episode is available for purchase on YouTube TV, Amazon, iTunes, and Google Play. • Learn More
On Sunday, December 20, the CNN original series This is Life with Lisa Ling broadcasted a new investigative report on the potential healing effects of psychedelics. In this new episode, journalist Lisa Ling interviews MAPS Founder Rick Doblin, Ph.D., and other notable figures in the field of psychedelic therapy. • Learn More
The Autumn 2020 edition of the MAPS Bulletin is now available online and being mailed to subscribers! We are proud to share our Annual Financial Report, artwork from visionary artist Autumn Skye spanning the front and back covers, and a collection of original articles full of psychedelic education. Read the new edition of the MAPS Bulletin.
The Way of the Psychonaut audiobook is available for purchase in the MAPS Store. The MAPS-published audiobook is a two-volume book set in single file. You can purchase access to the film and audiobook at thewayofthepsychonaut.com. The print book and Kindle version of The Way of the Psychonaut is also available for purchase.
You can join the field of psychedelic research by applying for one of our job opportunities with MAPS, MAPS Public Benefit Corporation (MAPS PBC), or MAPS Europe. Our newest opportunities with MAPS are the Director of Sales and Major Gifts and Chief of Staff to the Deputy Director. MAPS PBC is hiring a Temporary Clinical Data Scientist and a Clinical Research Associate Contractor.
We are currently seeking research volunteers for Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Trials are recruiting in Charleston, South Carolina, Boulder, Colorado, Fort Collins, Colorado, New Orleans, Louisiana, United States, Boston, Massachusetts, Los Angeles, California, and San Francisco, California. Volunteers will help contribute to scientific knowledge and will help us better understand if MDMA-assisted therapy works for treatment of PTSD. MAPS conducts clinical trials under the guidance and regulations of the U.S. Food and Drug Administration (FDA) in collaboration with federal regulators, including the Drug Enforcement Administration (DEA). To learn more about our clinical trials or apply to be a study participant, visit our website.
In this month’s edition of the MAPS Newsletter, you’ll also learn:
- Zendo Project: Beyond the Festival webinar recordings are now available for purchase
- MAPS is featured in a new video in Bloomberg
- New MAPS water bottles are available in the MAPS Store
Follow MAPS on Facebook, Twitter, Instagram, YouTube, LinkedIn, and reddit.
We’re looking forward to a new year of psychedelic research and education!
With appreciation,
Amy Mastrine
MAPS Web and Email Marketing Associate
Treating PTSD with MDMA-Assisted Therapy
MAPS and MAPS Public Benefit Corporation Announce Positive Result from Phase 3 Trial of MDMA-Assisted Therapy for PTSD
In November 2020, MAPS Public Benefit Corporation (MAPS PBC) completed data analysis of the first of two Phase 3 trials of MDMA-assisted therapy for treatment of posttraumatic stress disorder (PTSD). The results confirmed Phase 2 results and prior expectations from an independent interim analysis which determined there was a 90% or greater probability that the trial, when completed, would be of sufficient size to detect statistically significant results. Further, no unexpected or serious safety signals emerged during the course of the trial.
The results indicate MDMA-assisted therapy for PTSD may be an effective treatment for PTSD resulting from various types of trauma, including trauma occurring in childhood and in patients with dissociative subtype of PTSD, pending assessment by the U.S. Food and Drug Administration (FDA). Based on these results, MAPS will begin discussions with the FDA on ways to accelerate the timeframe for approval of this modality.
The Phase 3 trial, the first of its kind in scope and size, treated 90 participants who received 3 day-long MDMA or placebo sessions one month apart and 12 90-minute non-drug therapy sessions over approximately 3.5 months. The severity of PTSD symptoms was measured using the Clinician-Administered PTSD Scale for the DSM-5 (CAPS-5); measurements were taken before and after completion of treatment. Of these 90 participants, approximately half received MDMA-assisted therapy. The other half of participants, the control group, received placebo with identical therapy. A second Phase 3 clinical trial is currently enrolling participants.
Bessel van der Kolk, M.D., a leading PTSD researcher and author of the foundational book on PTSD, The Body Keeps the Score, served as Principal Investigator for the Boston site of the study. He noted, "The experience of having been traumatized profoundly alters perceptions; self-experience; and capacity to plan, imagine and anticipate. Since the results of this study mirror previously published results, we can expect to see fundamental shifts in our subjects' perspective on self-capacity, affect regulation, and attitude towards those around them. It takes a great deal of courage to address one’s PTSD, particularly when other treatments have failed. These results open the door to a powerful new pathway to healing once MDMA-assisted psychotherapy has been approved as a treatment for PTSD."
Phase 3 Trials of MDMA-Assisted Therapy for PTSD: Seeking Research Volunteers
We are currently seeking research volunteers for Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Volunteers will help contribute to scientific knowledge and will help us better understand if MDMA-assisted therapy works for the treatment of PTSD. MAPS conducts clinical trials under the guidance and regulations of the U.S. Food and Drug Administration (FDA) in collaboration with federal regulators, including the Drug Enforcement Administration (DEA). To learn more about our clinical trials or apply to be a study participant, visit our website.
We are recruiting participants in the following locations:
- Charleston, South Carolina, United States
- Boulder, Colorado, United States
- Fort Collins, Colorado, United States
- New Orleans, Louisiana, United States
- Boston, Massachusetts, United States
- Los Angeles, California, United States
- San Francisco, California, United States Private Practice
Not yet recruiting:
- New York, New York, United States
- San Francisco, California, United States Institution
- Madison, Wisconsin, United States
- New York, New York, United States
- Vancouver, British Columbia, Canada
- Be’er Ya’akov, Israel
- Tel Aviv, Israel
A Phase 1/2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in which One Member Has Chronic Posttraumatic Stress Disorder (PTSD) Shows MDMA-Assisted Therapy for PTSD in Couples May Reduce PTSD Symptoms and Improve Couples’ Happiness
The results of a MAPS-sponsored pilot study published on December 7, 2020, in the European Journal of Psychotraumatology found that MDMA-assisted therapy for PTSD in couples may reduce PTSD symptoms and improve couples’ happiness. Cognitive-Behavioral Conjoint Therapy (CBCT) for PTSD and MDMA-assisted therapy for PTSD resulted in significant reductions in PTSD symptoms and relational outcomes for couples. This initial trial included six couples with a range of baseline relationship satisfaction in which one member was diagnosed with PTSD resulting from a range of traumas including childhood physical abuse, childhood sexual abuse, and active military service. Read the press release here or visit the study webpage for more information.
Startle Testing with MDMA: Thirty-Fourth Participant Receives Experimental Treatment, Database Locked
On August 1, 2020, the thirty-fourth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, Ph.D., this study is conducted at Emory University in Atlanta, Georgia. The MAPS Public Benefit Corporation (MAPS PBC) locked the database for this study on November 4, 2020. This officially brings the data collection phase of the study to an end. With this final set of data, the research team will analyze the data and write a paper for submission to a peer-reviewed scientific journal. • Learn More
An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Disorder
Taking place in the United Kingdom, Germany, Portugal, Norway, the Czech Republic, and the Netherlands, this open-label Phase 2 study of MDMA-assisted therapy for PTSD will serve as the lead-in to the planned Phase 3 study in Europe providing an opportunity for clinical supervision of therapy teams to complete their training, and to validate assumptions made for statistical power calculations supporting the planned Phase 3 clinical trial. This study will also provide cross-cultural validation data on the updated version of the Primary Outcome measure, the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), which will be used in the Phase 3 study. In addition, the study will gather supportive data on the safety and effectiveness of manualized MDMA-assisted therapy. This study will be the first multi-center study of MDMA-assisted therapy for PTSD in Europe and will explore reproducibility of findings from FDA-regulated Phase 2 and Phase 3 trials to confirm the Phase 3 study design.
Study sites in the Czech Republic and the Netherlands are currently screening participants, screening at the Norway site and the second Netherlands site is expected to begin early in 2021. The sites in the United Kingdom and Germany require further permissions before they can begin screening, most likely in early 2021, and the study set-up in Portugal is still in an early stage. Data gathered in European trials is hoped to provide support for a planned Marketing Authorization Application for potential approval by the European Medicines Agency (EMA). For more information, please visit: mapseurope.eu/research or our webpage.
MDMA Therapy Training Program Update: December 2020
Seasons greetings from the Training & Supervision department! We hope you are finding care and connection this winter, and we wish you a happy new year!
Annie Mithoefer, B.S.N., and Michael Mithoefer, M.D. delivered a global online training November 5-6 and 9-12. The November online training included trainees in the Netherlands, Belgium, Norway, United Kingdom, Portugal, South Africa, Somaliland, Canada, and the United States.
Earlier this year the MDMA Therapy Training Program launched a training design initiative to support the growth and continued quality of the program. We completed a competency framework which outlines the essential knowledge, skills, and abilities therapy providers will need to develop in order to successfully offer MDMA-assisted therapy. The team is working with external contributors and various subject matter experts to develop additional curriculum for the MDMA Therapy Training Program.
Our program staff are in the process of evaluating technology and various online platforms to support the learning ecosystem for the MDMA Therapy Training Program. We plan to deliver trainings entirely online in 2021. We are excited about the possibility of expanding access to training with the shift to online education. We plan to re-open enrollment for the MDMA Therapy Training Program in early 2021. To receive updates on future trainings and training program admissions, sign up for the MDMA Therapy Training Program Newsletter.• Learn More
Support MAPS
November 2020 Giving Report: MAPS Raises Over $289,000 for Psychedelic Research and Education
In November 2020, we raised $328,478 in donations and pledges from over 850 supporters. Of this amount: $152,694 is for MDMA-related projects; $100,000 for health equity; $46,757 for general support; $27,000 for publishing; $1,747 for psychedelic harm reduction and peer support; $250 for ibogaine research; and $30 for marijuana research.
We extend a special thank you to our monthly donors who contributed a total of $16,725 in November. Your support is vital in making MAPS’ programs sustainable.
We are honored to support a number of like-minded organizations by providing a fiscal sponsorship so that contributions for their social benefit projects may be tax-deductible as allowed by law. An additional $89,996 was raised by organizations that MAPS fiscally sponsors including: Santa Fe Integrative Therapy (SFIT) ($28,364); ICEERS ($29,535); TheraPsil ($25,000); Ayahuasca Diaries ($5,000); Psychedelic Seminars ($1,800); Somatic Center Portland ($200); Bluelight ($45); Kaphi ($22); MAPS Canada ($20); and Bay Area Healers Resilience Fund ($10).
We extend a warm congratulations to Chacruna and VETS, Inc. on each achieving their 501(c)(3) status this year. We look forward to this new chapter in the growth of your organizations. Donations may now be made directly to Chacruna and VETS, Inc.
MAPS is pleased to welcome our new fiscal sponsorship grantees: Empyrean Temple Instituto Phaneros How We Heal Nautilus Sanctuary The Psychedelic Renaissance / Spelt Productions
Santa Fe Integrative Therapy (SFIT)
Gratitude
We appreciate donations of any size and are particularly grateful to the following supporters for their generous contributions of $1,000 or more:
Unrestricted
Anonymous ($3,000)
Annabet Berlin, Berlin Family Fund ($1,500)
Claus Derganc ($1,500)
Jacob Voges, New Wave Design and Verification ($1,500)
Donna Baier Stein ($1,000)
Rick Greenthal and Dr. Michelle Yount ($1,000)
Robert and Nancy Ley ($1,000)
MUDWTR ($1,000)
Ryan Orbuch ($1,000)
Christian Saenger ($1,000)
Gwen Swinarton ($1,000)
Cassandra Carlone Tacheny ($1,000)
Jiri Techet ($1,000)
Anonymous ($1,000)
Phase 3 for FDA/Capstone Campaign
Navy Seal Foundation ($50,000)
Phase 3 for EMA/Global Access
Carey and Claudia Turnbull ($100,000)
Zendo Project
Anonymous ($1,139)
Health Equity
David Bronner, Dr. Bronner’s Magic Soaps ($100,000)
Publishing
Psychedelic Literacy Fund ($27,000)
Fiscal Sponsorship Grantees
Thomas and Khaliya Ermacora ($29,500) – ICEERS
David Bronner, Dr. Bronner’s Magic Soaps ($25,000) – TheraPsil
Anonymous ($10,500) – Santa Fe Integrative Therapy (SFIT)
Tom McAllister ($7,500) – Santa Fe Integrative Therapy (SFIT)
Christopher Lindstrom ($5,000) – Ayahuasca Diaries
Carly Moore ($2,100) – Santa Fe Integrative Therapy (SFIT)
Rob Sprinz ($2,000) – Santa Fe Integrative Therapy (SFIT)
Colm Walker ($1,300) – Psychedelic Seminars
MAPS relies on the generosity of individual donors to achieve its mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic therapy research is yet available from governments or major foundations.
Together, we can legalize psychedelic medicine.
Donate now at maps.org/donate. Learn how to include MAPS in your will or estate plans.
We’re Hiring!
MAPS, MAPS Public Benefit Corporation (MAPS PBC), and MAPS Europe are currently hiring!
MAPS
- Chief of Staff to the Deputy Director
Remote - Director of Sales and Major Gifts
Remote - Financial Controller
Remote
MAPS Public Benefit Corporation (MAPS PBC):
- Adherence and Supervision Coordinator
Remote - Clinical Data Manager (CDM)
Remote - Clinical Research Associate – Contractor (Canada)
Remote - Document Control Specialist
Remote - Executive Assistant
Santa Cruz, California - Head of GCP Quality & Compliance
Remote - Manager, GxP Quality Assurance
Remote - Medical Monitor
Remote - Study Coordinator
Boulder and Denver, Colorado - Temporary Clinical Data Scientist
Remote
MAPS Europe:
- Independent Rater
Portugal and Germany - Clinical Research Associate – Portugal
Remote
Psychedelic Peer Support
Now Available for Purchase: Zendo Project: Beyond the Festival Webinar Recordings
We are excited to announce that video recordings from the Zendo Project: Beyond The Festival webinar series are now available for sale! Learn more about psychedelic peer support, harm reduction, and creating communities of compassionate care by browsing our offerings of educational content. • Learn More
Policy and Advocacy
DEA Issues Final Rule on December 17 Establishing a Clearinghouse for Production and Sale of Federally Legal Cannabis
Concluding a process that started in March with its announcement of a new rule governing the application of bulk manufacture licenses for marijuana, on December 17, 2020, DEA issued a final rule that essentially establishes DEA as a clearinghouse for all production and sale of federally legal cannabis. Instead of simplifying the process and acting on the dozens of pending applications, DEA’s new rules have failed to meaningfully address the field’s urgent needs for medicine and instead, add additional administrative hurdles that will ultimately hurt people seeking relief from medical cannabis.
For the last two decades, the U.S. Department of Justice has inconsistently applied international treaty obligations to justify a monopoly on production of cannabis by a single grower, while utterly failing to act on applications from other qualified producers, like Dr. Lyle Craker. Given the progress occurring at the United Nations, in other countries around the world, and with state-legal systems here in the United States, we are particularly disappointed to see the federal government continue to dig its heels in and restrict science. For more information and context, read this article from Marijuana Moment.
On December 2, 2020, the United Nations’ Commission on Narcotic Drugs made a momentus move by voting to remove cannabis and cannabis resin from the most restrictive of the international schedules—Schedule IV. The decision was based on a set of recommendations from the World Health Organization (WHO), made to the Commission in January 2019. While this change does not remove any internationally required controls on cannabis, this important move officially recognizes the potential therapeutic value of cannabis. Cannabis remains in Schedule I, which imposes the controls that member states must comply with, but removes it from Schedule IV, which is a sub-category of Schedule I that denotes high risk drugs with little to no therapeutic value. Inclusion in Schedule IV also leaves the option of maintaining a complete prohibition on those drugs up to the judgment of the member state.
Also on December 2, Professor Lyle Craker, a Professor of Botany and Plant Sciences at the University of Massachusetts – Amherst, and longtime collaborator with MAPS, filed a lawsuit against Attorney General Barr and the Drug Enforcement Administration (DEA) for egregious delay in taking any action on an application to grow cannabis for federally-approved clinical research. Prof. Craker filed this application, his second, in February 2017 and is yet to receive any indication of the agency’s intent to approve or deny it, to date. All other applications to grow federally-approved cannabis sit in the same limbo—creating, in effect, a near complete bar on cannabis drug development research in the United States. The DEA is currently stuck trying to thread the narrow needle the Department of Justice has created with its quiet-but-restrictive interpretation of international treaty obligations. The UN decision this month didn’t go far enough to directly undermine this interpretation on controls, but the recognition of medical applications for cannabis is an important international policy signal in the direction of more, not less, action in cannabis therapeutics.
In the same week, the U.S. House of Representatives, for the first time, passed a bill—the MORE Act—that would federally decriminalize cannabis by removing it from scheduling.
MAPS in the Media
- Study: MDMA-Assisted Therapy May Reduce Anxiety for Those Diagnosed with Life-Threatening Illness
- November 24, 2020
- Lawsuit Filed Against the DEA and Attorney General to Compel Issuance of Licenses to Manufacture Marijuana for Clinical Trials and Potential FDA Approval
- December 3, 2020
- MAPS-Sponsored Pilot Study: MDMA-Assisted Therapy for PTSD in Couples May Reduce PTSD Symptoms, Improve Couples’ Happiness
- December 7, 2020
- Marijuana Moment: Another Scientist Sues DEA To Cultivate Marijuana For Research Purposes
- December 3, 2020
- Bloomberg: Psychedelic Drugs Are Fueling a Mental Health Revolution
- November 23, 2020
- Jewish Telegraph Agency: Meet Rick Doblin, the Jewish Psychedelics Advocate Working to Turn a Club Drug Into Legal Medicine
- November 19, 2020
- Field Tripping Podcast: The Best Kind of Counter-Culture, Drug Using Criminal | Rick Doblin Pt. 1
- November 24, 2020
MAPS Store
The Way of the Psychonaut audiobook is available for purchase in the MAPS Store. The MAPS-published audiobook is a two-volume book set in single file. You can purchase access to the film and audiobook at thewayofthepsychonaut.com. The print book and Kindle version of The Way of the Psychonaut is also available for purchase.
This 32oz TKWide water bottle comes with the vacuum-insulated Wide Loop Cap which creates a full stainless steel interior, increases thermal performance, features Kleen Kanteen's TK Closure™ internal thread design, and has an easy-carry swivel loop. The MAPS Kleen Kanteen water bottle keeps contents hot for up to 22 hours or iced up to 75 hours. Made from stainless steel, it is BPA free and won't retain or impart flavors. As an optional add-on, purchase a wide spout Chug Cap attachment. Buy Now
Events
Browse our Event Calendar page for more opportunities.
Polaris Insight Center: Trainings for Clinicians, December 2020 – June 2021, San Francisco, California
Polaris Insight Center provides didactic, experiential, and residential trainings in ketamine-assisted therapy. These programs are designed to provide interested physicians, psychologists, therapists, nurses, and other healthcare professionals with principles and procedures of KAP and how to use ketamine in combination with psychotherapy in a clinical setting. • Learn More
Understanding Ketamine, January 23 & 24, 2021, Online
Ketamine is a dissociative anesthetic also classified as a psychedelic. In the last decade it has become frequently sought as a treatment for depression and mood disorders. This training is designed for therapists, psychologists, physicians, and other healthcare professionals who want to better understand the basics of ketamine and how they can ensure the best clinical outcomes for patients. •Learn More
More News
Your Neighbors Are Doing Psychedelics: Book 1: From the Club to the Clinic: MDMA by David E. Carpenter
This book follows the remarkable, psychedelic-assisted treatment of an ex-policeman named Nick Watchorn, who took the brave path in 2018 to be part of a government-sponsored scientific experiment to treat his severe PTSD. At 50 years old, Nick had suffered for 22 years from the terror of a mass shooting he experienced as a young cop. Prior to his decision to enter clinical trials using MDMA, Nick had no experience with psychoactive drugs. He was out of options and prepared for radical solutions — at any cost. Learn More
Participate in Psychedelic Research
MDMA Studies Sponsored by MAPS
MAPS sponsors clinical trials around the world that offer volunteers the opportunity to participate in our research studies. Our studies have strict enrollment criteria based on the goal of the study and the condition the study is investigating.
Phase 3 MDMA/PTSD trial participant enrollment is now open. Please bookmark our Participate in Research page and check it frequently for updates.
Thank you to Dr. Bronner’s for their company’s support of the MAPS Newsletter!